Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Action stimulants, antagonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CDH17 antagonists(Cadherin-17 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Esophagus | Phase 1 | Australia | ![]() | 30 May 2022 |
Adenocarcinoma of Esophagus | Phase 1 | Hong Kong | ![]() | 30 May 2022 |
Adenocarcinoma of large intestine | Phase 1 | Hong Kong | ![]() | 30 May 2022 |
Adenocarcinoma of large intestine | Phase 1 | Australia | ![]() | 30 May 2022 |
Bile Duct Neoplasms | Phase 1 | Australia | ![]() | 30 May 2022 |
Bile Duct Neoplasms | Phase 1 | Hong Kong | ![]() | 30 May 2022 |
Liver Cancer | Phase 1 | Hong Kong | ![]() | 30 May 2022 |
Pancreatic Cancer | Phase 1 | Australia | ![]() | 30 May 2022 |
Pancreatic Cancer | Phase 1 | Hong Kong | ![]() | 30 May 2022 |
Gastrointestinal Neoplasms | Phase 1 | United States | ![]() | - |
Not Applicable | - | wutyzixbfd(fkcddzetoh) = ayxkdrlcfw ymtquvfqkr (gupkuxhtmv, In - house CDH17 IHC Data) | - | 15 Sep 2024 | |||
Phase 1 | Gastrointestinal Neoplasms CDH17 Expressing | - | (qkqgvmjqso) = ARB202 a bispecific T-cell engager has shown tolerability up to 40ng/ml Cmax in circulation suggesting no clinically significant CD3 only binding cell activation at these levels. fsxcldbdqv (dftaaiwbiy ) View more | Positive | 03 Aug 2023 |